Enovis Corp

ENOV remains in a Stage 3 distribution under a sustained downtrend, with price trading below declining EMAs and the 200-day SMA. Medium-term directional bias is bearish until price can reclaim the $22.88–$24.37 resistance cluster with conviction. Short-term conditions are deeply oversold and lack evidence of exhaustion or strong buying, offering no reliable edge to add to shorts here. Execution should be deferred, stalking any relief rally into the 22.88–24.37 zone for rejection-based selling.

• ↑Earnings yield 1.91 and book-to-price 2.53 signal stock undervaluation
• ↑DonJoy Spinamic Hybrid Scoliosis Brace launch implies ~50% upside
• ↓Adjusted operating margin contracted 6.7 points to 4.5% in Q2